Suppr超能文献

巴基斯坦血液透析患者的高血压控制评估:一项前瞻性随访研究。

Evaluation of hypertension control among hemodialysis patients in Pakistan: a prospective follow-up study.

机构信息

Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan.

Department of Chemistry, M.S. Ramaiah Institute of Technology (affiliated to Visvesvaraya Technological University, Belgaum), Bengaluru, Karnataka, India.

出版信息

Blood Press Monit. 2023 Oct 1;28(5):253-259. doi: 10.1097/MBP.0000000000000656. Epub 2023 Jul 6.

Abstract

BACKGROUND

Hypertension is highly prevalent and uncontrolled among hemodialysis patients. In Pakistan published data does not provide enough information about the management and factors associated with uncontrolled hypertension in hemodialysis patients.

OBJECTIVE

This study was conducted to evaluate the factors influencing the pharmacotherapeutic management and control of hypertension in hemodialysis patients.

METHODS

A prospective follow-up study was conducted on hemodialysis patients who were enrolled at study sites between 1 June 2020 and 31 December 2020. The predialysis blood pressure (BP) readings were recorded as mean SBP and DBP at baseline and for each of 6 months. Multivariate analyses were applied to analyze the factors associated with uncontrolled hypertension in hemodialysis patients.

RESULTS

The average predialysis BP (SBP and DBP) of study participants at baseline visit was 158.41 and 87.22 mmHg respectively. After 6 months the study participants have 150.27 mmHg and 80.03 mmHg average predialysis SBP and DBP respectively. Only 28.1% of hemodialysis patients were on target BP after 6 months. Results of multivariate analysis have shown that the use of beta-blockers and calcium channel blockers (CCBs) were significantly associated with hypertension control at baseline [odds ratio (OR) = 1.432, P value = 0.034] (OR = 1.499, P value = 0.045) and at after 6 months (OR = 2.824, P value = 0.015) (OR = 1.883, P value = 0.032).

CONCLUSION

This study revealed that among the antihypertensive drugs, CCBs and beta-blockers provided better management in controlling hypertension among hemodialysis patients.

摘要

背景

高血压在血液透析患者中普遍且未得到控制。在巴基斯坦,已发表的数据并未提供有关血液透析患者高血压管理和相关因素的足够信息。

目的

本研究旨在评估影响血液透析患者药物治疗管理和高血压控制的因素。

方法

对 2020 年 6 月 1 日至 2020 年 12 月 31 日期间在研究地点登记的血液透析患者进行了前瞻性随访研究。记录了透析前血压(BP)读数,作为基线和每个 6 个月的平均收缩压(SBP)和舒张压(DBP)。应用多变量分析来分析与血液透析患者高血压未控制相关的因素。

结果

研究参与者基线时的平均透析前 BP(SBP 和 DBP)分别为 158.41mmHg 和 87.22mmHg。6 个月后,研究参与者的平均透析前 SBP 和 DBP 分别为 150.27mmHg 和 80.03mmHg。只有 28.1%的血液透析患者在 6 个月后达到目标 BP。多变量分析结果表明,β受体阻滞剂和钙通道阻滞剂(CCB)的使用与基线时(比值比[OR] = 1.432,P 值 = 0.034)和 6 个月时(OR = 2.824,P 值 = 0.015)的高血压控制显著相关(OR = 1.499,P 值 = 0.045)(OR = 1.883,P 值 = 0.032)。

结论

本研究表明,在降压药物中,CCB 和β受体阻滞剂在控制血液透析患者高血压方面提供了更好的管理。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验